By Regulatory Approvals — FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies Targeted Oncology
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. August 4, 2026.